188 related articles for article (PubMed ID: 26640079)
41. Botulinum neurotoxin treatment in children with cerebral palsy: validation of a needle placement protocol using passive muscle stretching and relaxing.
Warnink-Kavelaars J; Vermeulen RJ; Buizer AI; Becher JG
Dev Med Child Neurol; 2016 Dec; 58(12):1281-1287. PubMed ID: 27381267
[TBL] [Abstract][Full Text] [Related]
42. Systemic adverse events following botulinum toxin A therapy in children with cerebral palsy.
Naidu K; Smith K; Sheedy M; Adair B; Yu X; Graham HK
Dev Med Child Neurol; 2010 Feb; 52(2):139-44. PubMed ID: 20412252
[TBL] [Abstract][Full Text] [Related]
43. Botulinum toxin treatment in upper limb spasticity: treatment consistency.
Papavasiliou AS; Nikaina I; Bouros P; Rizou I; Filiopoulos C
Eur J Paediatr Neurol; 2012 May; 16(3):237-42. PubMed ID: 21862370
[TBL] [Abstract][Full Text] [Related]
44. Intensive therapy following upper limb botulinum toxin A injection in young children with unilateral cerebral palsy: a randomized trial.
Hoare B; Imms C; Villanueva E; Rawicki HB; Matyas T; Carey L
Dev Med Child Neurol; 2013 Mar; 55(3):238-47. PubMed ID: 23236956
[TBL] [Abstract][Full Text] [Related]
45. Development of an inventory of goals using the International Classification of Functioning, Disability and Health in a population of non-ambulatory children and adolescents with cerebral palsy treated with botulinum toxin A.
Nguyen L; Mesterman R; Gorter JW
BMC Pediatr; 2018 Jan; 18(1):1. PubMed ID: 29301539
[TBL] [Abstract][Full Text] [Related]
46. Questionnaire about the adverse events and side effects following botulinum toxin A treatment in patients with cerebral palsy.
Blaszczyk I; Foumani NP; Ljungberg C; Wiberg M
Toxins (Basel); 2015 Nov; 7(11):4645-54. PubMed ID: 26561833
[TBL] [Abstract][Full Text] [Related]
47. A French observational study of botulinum toxin use in the management of children with cerebral palsy: BOTULOSCOPE.
Chaléat-Valayer E; Parratte B; Colin C; Denis A; Oudin S; Bérard C; Bernard JC; Bourg V; Deleplanque B; Dulieu I; Evrard P; Filipetti P; Flurin V; Gallien P; Héron-Long B; Hodgkinson I; Husson I; Jaisson-Hot I; Maupas E; Meurin F; Monnier G; Pérennou D; Pialoux B; Quentin V; Moreau MS; Schneider M; Yelnik A; Marque P
Eur J Paediatr Neurol; 2011 Sep; 15(5):439-48. PubMed ID: 21745754
[TBL] [Abstract][Full Text] [Related]
48. Ketamine procedural sedation in the emergency department of an urban tertiary hospital in Dar es Salaam, Tanzania.
Coralic Z; Sawe HR; Mfinanga JA; Cortez A; Koehl J; Siroker H; Reynolds TA
Emerg Med J; 2018 Apr; 35(4):214-219. PubMed ID: 29358491
[TBL] [Abstract][Full Text] [Related]
49. Intramuscular botulinum toxin prior to comprehensive rehabilitation has no added value for improving motor impairments, gait kinematics and goal attainment in walking children with spastic cerebral palsy.
Schasfoort F; Pangalila R; Sneekes EM; Catsman C; Becher J; Horemans H; Stam HJ; Dallmeijer AJ; Bussmann JBJ
J Rehabil Med; 2018 Aug; 50(8):732-742. PubMed ID: 30080235
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of a mixture of ketamine, midazolam and atropine for procedural sedation in paediatric oncology: a randomised study of oral versus intramuscular route.
Bhatnagar S; Mishra S; Gupta M; Srikanti M; Mondol A; Diwedi A
J Paediatr Child Health; 2008 Apr; 44(4):201-4. PubMed ID: 17927726
[TBL] [Abstract][Full Text] [Related]
51. Sedation with midazolam and ketamine for invasive procedures in children with malignancies and hematological disorders: a prospective study with reference to the sympathomimetic properties of ketamine.
Meyer S; Aliani S; Graf N; Reinhard H; Gottschling S
Pediatr Hematol Oncol; 2003 Jun; 20(4):291-301. PubMed ID: 12746161
[TBL] [Abstract][Full Text] [Related]
52. Repeat Intravenous Ketamine Dosing in Children Undergoing Emergency Department Procedural Sedation.
Forrester KR; Thomas SM; Gupta NK; Karumuri M; Gerard JM
J Emerg Med; 2019 Jan; 56(1):1-6. PubMed ID: 30415803
[TBL] [Abstract][Full Text] [Related]
53. High doses of a new botulinum toxin type A (NT-201) in adult patients with severe spasticity following brain injury and cerebral palsy.
Intiso D; Simone V; Di Rienzo F; Iarossi A; Pazienza L; Santamato A; Maruzzi G; Basciani M
NeuroRehabilitation; 2014; 34(3):515-22. PubMed ID: 24473245
[TBL] [Abstract][Full Text] [Related]
54. A double-blind, randomised, placebo-controlled trial of oral midazolam plus oral ketamine for sedation of children during laceration repair.
Barkan S; Breitbart R; Brenner-Zada G; Feldon M; Assa A; Toledano M; Berkovitch S; Shavit I; Kozer E
Emerg Med J; 2014 Aug; 31(8):649-53. PubMed ID: 23686730
[TBL] [Abstract][Full Text] [Related]
55. Motor endplate-targeted botulinum toxin injections of the gracilis muscle in children with cerebral palsy.
Van Campenhout A; Bar-On L; Desloovere K; Huenaerts C; Molenaers G
Dev Med Child Neurol; 2015 May; 57(5):476-83. PubMed ID: 25557985
[TBL] [Abstract][Full Text] [Related]
56. Effect of botulinum toxin type A on cerebral palsy with upper limb spasticity.
Yang TF; Fu CP; Kao NT; Chan RC; Chen SJ
Am J Phys Med Rehabil; 2003 Apr; 82(4):284-9. PubMed ID: 12649654
[TBL] [Abstract][Full Text] [Related]
57. Clinical outcomes of botulinum toxin injection in patients with cerebral palsy and esotropia.
Ameri A; Mirmohammadsadeghi A; Makateb A; Bazvand F; Hosseini S
Strabismus; 2015; 23(1):8-13. PubMed ID: 25789846
[TBL] [Abstract][Full Text] [Related]
58. [Development of motor functions and manual abilities in pediatric patients with spastic cerebral palsy after botulinum toxin treatment and complex rehabilitation].
Klochkova OA; Kurenkov AL; Namazova-Baranova LS; Mamed'iarov AM; Zherdev KV
Vestn Ross Akad Med Nauk; 2013; (11):38-48. PubMed ID: 24640730
[TBL] [Abstract][Full Text] [Related]
59. Use of botulinum toxin type A in pediatric patients with cerebral palsy: a three-center retrospective chart review.
Gormley ME; Gaebler-Spira D; Delgado MR
J Child Neurol; 2001 Feb; 16(2):113-8. PubMed ID: 11292216
[TBL] [Abstract][Full Text] [Related]
60. Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children With Cerebral Palsy and Spastic Equinus Foot Deformity.
Dai AI; Aksoy SN; Demiryürek AT
J Child Neurol; 2016 Feb; 31(2):184-9. PubMed ID: 25999301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
